---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136680"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:00:24.918406+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch

## Summary
- Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.
- Compensation: $500k base salary, 40% target bonus; severance includes 9-month base pay (12-month + full target bonus if change in control within 12 months).
- Expected Jan 10, 2025 grant of stock option for 100,000 shares; 25% vests Dec 16, 2025, remainder in 36 monthly installments.
- Ms. Kalofonos previously CCO at Fulcrum Therapeutics; led ELAHERE launch at ImmunoGen and TAKHZYRO global launch at Takeda/Shire.

## SEC filing metadata
- accession: 0000950170-24-136680
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/0000950170-24-136680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/crnx-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136680
- JSON: https://secwatch.observer/filing/0000950170-24-136680.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.